NEW YORK Ohr Pharmaceutical has packed up and headed eastward, the drug maker said.
Ohr, formerly based in Salt Lake City on an “interim” basis, announced Tuesday that it had moved to New York. The company is developing drugs such as Evizon, for the web form of age-related macular degeneration, and OHR/AVR 118, for cancer cachexia, a severe wasting disorder that hits late-stage cancer patients.
“We are actively developing two later-stage drugs and need a convenient and accessible base of operations closer to our scientists,” Ohr CEO Irach Taraporewala said. “We look forward to communicating with investors and the biotech community as we progress throughout the clinical trial and commercialization stages.”